Switch View
© PR Newswire
04.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus Holdings, Inc. (LNTH) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
BENSALEM, Pa., Nov. 4, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH).
IF YOU...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA) have opportunity to lead the securities fraud class action lawsuit....
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
Baxter International, Inc. (BAX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX) have opportunity to lead the securities fraud class action lawsuit....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
04.11.2025
ISIN: US68062P1066
Olema Pharmaceuticals, Inc.
OLMA
LISTED
NASDAQ
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
04.11.2025
ISIN: FR0010417345
Dbv Technologies SA
DBV
LISTED
EURONEXT
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
News Preview
Châtillon, France, November 4, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
BENSALEM, Pa., Nov. 4, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX).
IF...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
News Preview
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: DK0011048619
BioPorto A/S
BIOPOR
LISTED
CPH
Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs
News Preview
November 4, 2025Announcement no. 23...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: DK0011048619
BioPorto A/S
BIOPOR
LISTED
CPH
Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025
News Preview
November 4, 2025 Announcement no. 22...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: DK0011048619
BioPorto A/S
BIOPOR
LISTED
CPH
Progress Update on BioPorto’s Adult Clinical Study
News Preview
November 4, 2025Announcement no. 21...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US09077A1060
Biomea Fusion Inc
BMEA
LISTED
NASDAQ
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
News Preview
SAN CARLOS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the third quarter ended September 30, 2025, and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US45784A1043
InnovAge Holding Corp
INNV
LISTED
NASDAQ
InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2025
News Preview
INNOVAGE ANNOUNCES FINANCIAL RESULTS FOR THE FISCAL FIRST QUARTER ENDED SEPTEMBER 30, 2025...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
04.11.2025
ISIN: US18914F1030
Clover Health Investments Corp
CLOV
LISTED
NASDAQ
Clover Health Reports Third Quarter 2025 Results
News Preview
Business Highlights:...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US00773J2024
Spyre Therapeutics Inc
SYRE
LISTED
NASDAQ
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US34385P1084
Standard BioTools Inc
LAB
LISTED
NASDAQ
Standard BioTools Reports Third Quarter 2025 Financial Results
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US92243G1085
Vaxcyte Inc
PCVX
LISTED
NASDAQ
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
News Preview
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US8808811074
Terns Pharmaceuticals Inc
TERN
LISTED
NASDAQ
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
News Preview
FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equi...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US15678C1027
Ceribell, Inc.
CBLL
LISTED
NASDAQ
Ceribell Reports Third Quarter 2025 Financial Results
News Preview
SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US87650L1035
Tarsus Pharmaceuticals Inc
TARS
LISTED
NASDAQ
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
News Preview
Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US82657M1053
Sight Sciences Inc
SGHT
LISTED
NASDAQ
Sight Sciences to Present at Two Upcoming Investor Conferences
News Preview
MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Stifel 2...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: NL0015002CX3
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
News Preview
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability targets.
QIAGEN reaffirmed its FY 2025 outlook for net sales growth of about 4-5% CER (about 5-6% CER core sales excluding divestments) and raised its...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: NL0015002CX3
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
News Preview
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research.
The acquisition will significantly expand QIAGEN’s Sample technologies portfolio into the fast-growing single-cell seq...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: NL0015002CX3
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN kündigt CEO-Nachfolge an
News Preview
Ad-hoc-Mitteilung gemäß Art. 17 Marktmissbrauchsverordnung
QIAGEN kündigt CEO-Nachfolge an
Venlo, Niederlande, 4. November 2025 – QIAGEN N.V. gibt bekannt, dass Thierry Bernard als Chief Executive Officer und Geschäftsführer zurücktreten wird, sobald ein Nachfolger ernannt worden ist.
Der Aufsichtsrat und Thierry Bernard sind übereingekommen, da......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: NL0015002CX3
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN announces CEO transition plan
News Preview
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
QIAGEN announces CEO transition plan
Venlo, the Netherlands, November 4, 2025 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that Thierry Bernard will step down as Chief Executive Officer and Managing Director once a successor is appointed.
The Superv......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: NL0015002CX3
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN to return approximately $500 million to shareholders through a synthetic share repurchase
News Preview
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
QIAGEN to return approximately $500 million to shareholders through a synthetic share repurchase
Venlo, the Netherlands, November 4, 2025 – QIAGEN N.V. announces a plan to return up to approximately $500 million to shareholders through a synthetic share repurchase that combines a di......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: NL0015002CX3
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN zahlt rund USD 500 Millionen durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück
News Preview
Ad-hoc-Mitteilung gemäß Art. 17 Marktmissbrauchsverordnung
QIAGEN zahlt rund USD 500 Millionen durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück
Venlo, Niederlande, 4. November 2025 – QIAGEN N.V. gibt Pläne bekannt, mittels eines synthetischen Aktienrückkaufs bis zu rund $500 Mio. an Aktionärinnen und Aktionäre ......
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: NL0010696654
Uniqure NV
QURE
LISTED
NASDAQ
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an invest...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
News Preview
Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the investor presentation issued by Alcon Inc. (“Alcon”) (NYSE: ALC) regarding its proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR’s outstanding common stock, continues to urge its fell...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US0029421007
Aardvark Therapeutics Inc
AARD
LISTED
NASDAQ
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
News Preview
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment landscape ...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US16359R1032
Chemed Corp
CHE
LISTED
NYSE
Chemed Corporation to Present at the UBS 2025 Global Healthcare Conference
News Preview
CINCINNATI, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2025 Global Healthcare Conference on Tuesday, November 11, 2025, at approximately 2:00 p.m. (ET) at the PGA National Resort in Palm Beach Gardens, Florida....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
News Preview
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technologyAccelerated implementation of strategy through better monetization of technology and transitioning to an asset-lighter business modelAgreement includes approximately US$ 350 m in cash for...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US59267L1070
Metsera, Inc.
MTSR
LISTED
NASDAQ
Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"
News Preview
Novo Nordisk Amended Proposal Values Metsera at up to $
86.20
per Share, a Total of Approximately $
10.0
Billion
Superior to Revised Pfizer Proposal that Valued Metsera at up to $...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US09073M1045
Bio-Techne Corp
TECH
LISTED
NASDAQ
AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
News Preview
Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients.
Bio-Techne's COMET™ platform and Nucleai's multimodal spatial operating...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in Baxter International, Inc. Lawsuit - BAX
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit....
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics, Incorporated Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit....
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before November 10, 2025 to Discuss Your Rights - LNTH
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit....
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
December 8, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ATYR
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit....
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US0028241000
Abbott Laboratories
ABT
LISTED
NYSE
Abbott HeartMates Community Delivers Holiday Cheer in Hallmark Channel's New Movie "The More the Merrier"
News Preview
Movie to feature cameos from youth who have overcome significant heart health challenges and are part of the Abbott HeartMates community as well as professional football player and HeartMates ambassador Damar Hamlin
"The More the Merrier" is the first Hallmark m...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MLTX
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit....
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit....
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: IE00BGH1M568
Perrigo Company PLC
PRGO
LISTED
NYSE
Perrigo to Attend Jefferies Consumer Conference
News Preview
DUBLIN, Nov. 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to participate in one-on-one investor meetings at the Jefferies Miami Consumer Conference on T...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
Novo Nordisk submits updated proposal to acquire Metsera, Inc.
News Preview
Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US8753722037
Tandem Diabetes Care Inc
TNDM
LISTED
NASDAQ
Tandem Diabetes Care Achieves ISO/IEC 27001:2022 Certification, Reinforcing Commitment to Global Data Security Standards
News Preview
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achieved ISO/IEC 27001:2022 Certification from Insight Assurance, affirming Tandem’s company-wide commitment to cybersecurity, data protection, and operational integrity. As Tandem continues to expand internationally, the ISO/I...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US23284F1057
CytomX Therapeutics Inc
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
News Preview
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
News Preview
Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD’s Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD’s Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE0006595101
Mediclin AG
MED
LISTED
XETR
Geschäftsentwicklung im Rahmen der Erwartungen
News Preview
Offenburg, 4. November 2025
MEDICLIN auf Kurs: Geschäftsentwicklung im Rahmen der Erwartungen
Konzernbetriebsergebnis beträgt 48,9 Mio. Euro (9M 2024: 34,5 Mio. Euro)
Konzernumsatz liegt bei 586,9 Mio. Euro (9M 2024: 558,2 Mio. Euro)
Gesamtauslastung mit 86,8 % stabil
O......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE0006595101
Mediclin AG
MED
LISTED
XETR
business development in line with expectations
News Preview
Offenburg, 4 November 2025
MEDICLIN on track: business development in line with expectations
Group operating result amounts to EUR 48.9 million (9M 2024: EUR 34.5 million)
Consolidated group sales amounts to EUR 586.9 million (9M 2024: EUR 558.2 million)
Overall capacit......
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: KYG2545C1042
Crescent Biopharma, Inc.
CBIO
LISTED
NASDAQ
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
News Preview
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US69404D1081
Pacific Biosciences of California Inc
PACB
LISTED
NASDAQ
PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China
News Preview
NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period"). A class action...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Delaware First Health and the Centene Foundation Announce Grant Program Recipients
News Preview
Grants awarded to Delaware community-based organizations tackling housing insecurity and transportation barriers
NEWARK, Del., Nov. 4, 2025 /PRNewswire/ -- Delaware First Health, a leading Medicaid managed care organization in Delaware, and the Centene Foundatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US87583X1090
Tango Therapeutics Inc
TNGX
LISTED
NASDAQ
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
News Preview
– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– ...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US20454B1044
Compass Therapeutics Inc.
CMPX
LISTED
NASDAQ
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
News Preview
BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5-9, 2025, in Nat...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US1374041093
Candel Therapeutics, Inc.
CADL
LISTED
NASDAQ
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
News Preview
NEEDHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies to help patients fight cancer, today announced it will deliver three presentations at the Society for Immunotherapy of Cancer (SITC) 40th An...
Themefolio
Profiler
Peergroup
© Newsfile
04.11.2025
ISIN: US29415V1098
Envoy Medical, Inc.
COCH
LISTED
NASDAQ
Envoy Medical Announces First Three Patients Enrolled in Final Stage of Acclaim(R) Cochlear Implant Pivotal Clinical Trial
News Preview
Rapid patient enrollment underscores strong market interest and reinforces commercialization opportunity for fully implanted cochlear implantsWhite Bear Lake, Minnesota--(Newsfile Corp. - November 4, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions,...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US1407553072
Tvardi Therapeutics Inc
TVRD
LISTED
NASDAQ
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
News Preview
Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will present at the Jefferies Global Healthcare Conference in London, UK, on Tuesday, Nov...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US81728J1097
Sensus Healthcare, Inc.
SRTS
LISTED
NASDAQ
CMS Establishes Coding Validating Sensus SRT for Treating Non-Melanoma Skin Cancer
News Preview
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the Centers for Medicare & Medicaid Services (CMS) has published a distinct set of treatment codes specific to the...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US02043Q1076
Alnylam Pharmaceuticals Inc
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:
UBS Global Healthcare Conference on Monday, November 10, 2025, at 10:15 AM ET in Palm Beach Gardens, Florida
Jefferies Global Healthcare Conference o...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US24661P8077
Delcath Systems, Inc.
DCTH
LISTED
NASDAQ
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025.
Third Quarter 2025 Financial Results
Total revenue of $20.6 million, com...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US22407B1089
Coya Therapeutics, Inc.
COYA
LISTED
NASDAQ
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced results of an in vivo animal study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA investigational proprietary biologic combination) i...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
